Human BioSystems
Human BioSystems Granted Their 4th U.S. Patent: #7,083,910 ‘Preservation of Blood Platelets with Citrate’
Corporate news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Human BioSystems Granted Their 4th U.S. Patent: #7,083,910 ‘Preservation of
Blood Platelets with Citrate’
Palo Alto, CA – August 2nd, 2006 – (OTCBB:HBSC) Human BioSystems (“HBS” or
“Company”) announced today that it has been granted its fourth patent from
the U.S. Patent Office. Patent #7,083,910, “Preservation of Blood Platelets
with Citrate” should greatly contribute in the area of blood platelet
preservation for the two major recipient groups of blood platelets: cancer
patients that have undergone chemotherapy and/or radiation treatment (about
70%), and trauma patients suffering from extensive bleeding.
Blood platelets are the congealing component in blood. Before platelets can
be released to the medical community for use by human patients, they must
undergo a number of tests to assure their purity, which can take one to two
days to complete. Then they must be transported to the medical facilities
which can add more time. Thus, there is a very limited shelf-life left for
these platelets once they are available for use.
Current technology provides for the storage of platelets at room
temperature. This allows any bacteria present to grow rapidly over the
current 5-day allowable shelf period. The extra storage days possible with
the use of the HBS cold storage method should provide a dramatic decrease
in the cost and the waste that is inherent in the current blood platelet
storage methodology. It should also help keep blood platelets more
bacteria free.
“Our newest patent covers the process of cooling blood platelets to near
zero degrees Centigrade to keep them fresh and preserved for greater than
the current standard of 5 days. We anticipate being able to extend this
process to 7 days and beyond. This will reduce the current need to discard
stored platelets that have been preserved by existing methods. By
developing a cooling method that prolongs the preservation of platelets, we
believe this will greatly reduce the risk of bacterial infection while
increasing the availability of essential medical resources required to
treat cancer and trauma patients,” explained Dr. David Winter, President of
Human BioSystems.
In the past month Human BioSystems has announced the completion of the
second independent test of their blood platelet preservation technology and
their preparation for application to the FDA for a license to begin human
testing.
Human BioSystems is a developer of preservation platforms for organs and
other biomaterials. The Company, which is headquartered in Palo Alto,
California with research facilities in Michigan, has made significant
progress in its nine-year history. This fourth patent is another milestone
for Human BioSystems. HBS also announced recently the signing of a letter
of intent to enter the BioFuels business through the acquisition of two
ethanol production facility projects from EXL III.
Contact:
Human BioSystems Investor Relations Investor Relations
Harry Masuda Yes International Concept Communications, LLC
CEO Rich Kaiser James D. Caldwell
(650) 323-0943 (800) 631-8127 (727) 447-0514
hmasuda@humanbiosystems.com rich@yesinternational.com jc@conceptcg.com
Certain statements contained herein are “forward-looking” statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, results from ongoing research
and development as well as clinical studies, failure to obtain regulatory
approval for the Company’s products, if required, failure to develop a
product based on the Company’s technology, failure of any such products to
compete effectively with existing products, the inability to find a
strategic partner or to consummate a relationship with a potential
strategic partner on acceptable terms, and other factors discussed in
filings made by the Company with the Securities and Exchange Commission
(c)DGAP 04.08.2006
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found